Continuous post-market safety monitoring
Hattersley Pharmaceuticals maintains continuous pharmacovigilance protocols to monitor therapeutic safety, evaluate potential adverse reactions, and deliver expedited safety documentation to global health authorities.
24/7
global surveillance monitoring
< 15 days
expedited ICSR submission
100%
batch traceability integration
Adverse event reporting workflow
Report Intake
Clinical Assessment
Regulatory Submission
Adverse event observations, patient parameters, and batch serial numbers are received through encrypted safety intake channels.
Physicians and safety specialists evaluate causality, reaction severity, and signal detection metrics against clinical trial databases.
Validated safety reports are formatted to ICH E2B standards and transmitted to regulatory authorities within statutory deadlines.
Submit medical safety report
Healthcare professionals, hospital pharmacists, and patients may submit confidential adverse event disclosures using the encrypted form below.